Lexaria Bioscience Corp (LEXX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 08/31
| 08-2020 | 08-2019 | 08-2018 | 08-2017 | 08-2007 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -4,085 | -4,158 | -6,609 | N/A | N/A |
| Depreciation Amortization | 146 | 61 | 2 | N/A | N/A |
| Accounts receivable | -91 | -139 | -246 | N/A | N/A |
| Other Working Capital | -194 | 80 | -371 | N/A | N/A |
| Other Operating Activity | 1,605 | 1,151 | 4,706 | 0 | 0 |
| Operating Cash Flow | $-2,619 | $-3,006 | $-2,518 | $N/A | $N/A |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 7 | N/A | N/A | N/A | N/A |
| PPE Investments | N/A | -646 | N/A | N/A | N/A |
| Purchase Of Investment | N/A | N/A | -70 | N/A | N/A |
| Purchase Sale Intangibles | -34 | -123 | -85 | N/A | N/A |
| Other Investing Activity | -34 | -123 | -85 | 0 | 0 |
| Investing Cash Flow | $-27 | $-769 | $-155 | $N/A | $N/A |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 31 | N/A | N/A | N/A | N/A |
| Debt Repayment | -45 | N/A | N/A | N/A | N/A |
| Common Stock Issued | 2,668 | 2,333 | 1,867 | N/A | N/A |
| Other Financing Activity | 0 | 1,000 | 0 | 0 | 0 |
| Financing Cash Flow | $2,654 | $3,333 | $1,867 | $N/A | $N/A |
| Beginning Cash Position | 1,285 | 1,727 | 2,533 | N/A | N/A |
| End Cash Position | 1,294 | 1,285 | 1,727 | N/A | N/A |
| Net Cash Flow | $9 | $-442 | $-806 | $N/A | $N/A |
| Free Cash Flow | |||||
| Operating Cash Flow | -2,619 | -3,006 | -2,518 | N/A | N/A |
| Capital Expenditure | N/A | -646 | N/A | N/A | N/A |
| Free Cash Flow | -2,619 | -3,652 | -2,518 | 0 | 0 |